CLGN
CollPlant Biotechnologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.56
−1.79%Year over year
Reported trailing growth
- Revenue
- -86.8%
- EBITDA
- +2.9%
- EBIT
- +7.0%
- EPS
- -94.8%
- Free cash flow
- -9.1%
- Operating cash flow
- -10.3%
Forward estimates
Based on analyst estimates
- Revenue
- +643.7%
- EBITDA
- +85.5%
- EPS
- +80.2%
Three-year CAGR
- Revenue
- +99.4%
- EBITDA
- +32.1%
- EBIT
- +33.4%
- Net income
- +30.8%
- EPS
- +35.2%
- Free cash flow
- +35.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026